Clinician satisfaction with treatment outcomes among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S in PROSES study: Analysis by concomitant medication use

Abstract

Introduction: The objective of this analysis was to evaluate clinician satisfaction with treatment outcomes, stratified by the use of concomitant acne medications, among AV patients administered sarecycline in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROSES) was conducted with moderate-to-severe non-nodular AV patients >9 years who were prescribed sarecycline in real-world community practices in the US. Clinician satisfaction with sarecycline treatment outcomes was assessed on a five-point adjectival response scale (1 (very dissatisfied)-5 (very satisfied)). Proportion of patients for whom clinicians reported very satisfied/satisfied was analyzed, stratified by the use of any concomitant AV medication during the study (Yes vs. No (monotherapy)). Results: A total of 253 AV patients completed the study (adults 60.08% (mean age 26.63); pediatric 39.92% (mean age 14.81); female: 66.40%; white/Caucasian: 68.38%, African American: 8.70%; other races: 22.92%). Per IGA at baseline, 86.56% & 13.44% had moderate and severe AV, respectively. Key concomitant treatments for AV observed during the study included: topical retinoids (24.51%), topical antibiotics (13.44%), benzoyl peroxide (5.93%), topical dapsone (5.14%) and other (17.00%; predominantly adapalene/benzoyl peroxide). Half of the patients (49.80%) were on sarecycline monotherapy (i.e., did not use any concomitant treatments for AV). In the overall study cohort, at week-12, clinicians reported very satisfied/satisfied with sarecycline treatment outcomes for 88.14% of patients. At week-12, clinician satisfaction (very satisfied/satisfied) was 88.98% among patients using concomitant AV medications, and 87.30% among patients using no concomitant AV medications (i.e., on sarecycline monotherapy). Conclusion: Within the study cohort administered sarecycline, a narrow-spectrum, tetracycline-derived antibiotic, for 12 weeks, overwhelming majority of clinicians were very satisfied/satisfied with sarecycline treatment outcomes at week-12, and clinician satisfaction was similar among patients on sarecycline monotherapy and those on concomitant AV medications.